You are here: Home Categories Prostate Cancer
ASCO 2012 - Effect of neoadjuvant abiraterone acetate plus leuprolide acetate on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: Results of a randomized phase 2 study - Editor's Commentary

ASCO 2012 - Effect of neoadjuvant abiraterone acetate plus leuprolide acetate on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: Results of a randomized phase 2 study - Editor's Commentary

Published on 25 June 2012
  • Print

BERKELEY, CA (UroToday.com) -

Presentation of the New Paradigms for Hormone Therapy in Prostate Cancer
at the ASCO Annual Meeting
To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.
Tags:

Prostate Cancer

caselectures

mehlhaff270

nih role of active surveillance in the management of men with localized prostate cancer

penson sipuleucelX

scardino restaging